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We investigated the clinicopathologic signiﬁcance of HIF-1, CXCR4, and VEGF expression using immumohistochemistry in
human colon cancer. HIF-1, CXCR4, and VEGF high expression levels were correlated positively with TNM stage, lymph node
involvement, and distant metastasis Furthermore, we found that combined high expression of any two of the three molecules
(P = .028 for HIF-1/CXCR4, P = .007 for HIF-1/VEGF, and P = .004 for CXCR4/VEGF) had stronger correlation with
lymph node metastasis than did each alone. However, a relationship with distant metastasis is seen only with the combinations
CXCR4/VEGF(P = .069forHIF-1/CXCR4,P = .062forHIF-1/VEGF,andP = .035forCXCR4/VEGF)ascomparedwiththoseof
single molecule high expression alone. Combined expression of all three molecules strongly correlates with lymph node metastasis
and distant metastasis. The mRNA expression of HIF-1, CXCR4, and VEGF were quantiﬁed by real-time PCR in diﬀerent colon
cancer tissue samples, the experiment results shown that fresh colon tissue samples signiﬁcantly overexpressed CXCR4 and VEGF
mRNAcomparedwithnegativecontrol.Therefore,thedisease-freesurvivalofallpatientsaftercurativeresectioncanbeconsidered
in association with all three markers expression.
1.Introduction
Colon cancer is one of the most common cancers frequently
metastasizing to the liver, lymph nodes, and peritoneum [1].
Currently, radical surgery represents the standard method
of therapy. Adjuvant therapy such as chemotherapy and
radiation therapy have been widely applied, but colon cancer
controlattheadvancedstageremainsdiﬃcult[2].The5-year
survival rate for patients with the spread of disease to distant
sites is approximately 19% [3]. Therefore, it is necessary to
evaluate whether some metastasis-related molecules can be
used as prognostic markers for metastasis of colon cancer.
Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric
basic helix-loop-helix transcription factor composed of
two subunits, HIF-1α and HIF-1β [4]. HIF-1α is the key
regulatory component because it is degraded rapidly in
normoxic conditions but is stabilized and activated during
hypoxia and also is one of the key factors promoting
carcinogenesis independent of histogenetic origin [5]. In
clinical samples, HIF-1α is found elevated and correlates
with tumor progression, aggressive behavior, and patient
prognosis in several types of carcinoma including those of
the ovary, breast, prostate, lung, renal, glial, and melanoma
[6].
HIF-1 has emerged as a critical regulator of the cellular
response to hypoxia since it is ubiquitously expressed and
induces the expression of many hypoxia-inducible genes
(HRE) [7]. A gene reported to be positively regulated
by HIF-1α is CXC chemokine receptor 4 (CXCR4) [8].
Chemokines comprise a superfamily of small cytokines with
the ability to chemoattract cells to target tissues. Interactions
betweenCXCR4anditsligandCXCL12(stromalcell-derived2 Clinical and Developmental Immunology
Table 1: Correlation of HIF-1α, CXCR4, and VEGF expression with clinicopathologic features in colon cancer. Sections were subjected to
routine deparaﬃnization and rehydration. Antigen retrieval was achieved by microwaving in citrate buﬀer for 10min. The endogenous
peroxidase activity was inhibited by incubation with 3% hydrogen peroxide. The specimens were reacted overnight with anti-HIF-1α
antibodies, anti-CXCR4 antibodies, and anti-VEGF antibodies, then were incubated with rat anti-mouse-IgG2b-horseradish peroxidase.
The sections were then counterstained with hematoxylin and mounted (see Section 2). Staining intensity and percentage of positive tumor
cells were assessed. Multiplication of the intensity and the percentage scores gave rise to the ﬁnal staining score: 0 (negative), + (1–4), ++
(5–8), and +++ (9–12). For statistical analysis, tumors having staining scores of 0 or + were designated the low expression group, and
tumors with scores of ++ or +++ the high expression group. The correlation between clinicopathologic parameters and HIF-1α,C X C R 4 ,
and VEGF expression were analyzed by Chi-squared test or Fisher’s exact test. Abbreviations: HIF-1α: Hypoxia-inducible factor-1; CXCR4:
CXC chemokine receptor 4; VEGF: vascular endothelial growth factor; HPP: hyperplastic polyps; TNM: tumor-node-metastasis.
Clinicopatholog-
ic parameters Case No.
HIF-1α expression P value CXCR4 expression P value VEGF expression P value
Low High Low High Low High
Total cases 68 38 30 27 41 24 44
Age
≤60 19 12 10 P = .878 81 1 P = .801 91 0 P = .195
>60 49 26 20 19 30 15 34
Tissue type
Normal colonic
tissue 10 10 0 P = .002
a 10 0 P<. 001
a 10 0 P<. 001
a
HPP 8 8 0 P = .006
b 80 P<. 001
b 80 P<. 001
b
Colon cancer 68 38 30 P = .019c 27 41 P = .001c 24 44 P = .001c
Sex
Male 41 24 17 P = .587 15 26 P = .639 14 27 P = .807
Female 27 14 13 11 15 10 17
Tumor size
≤5cm 27 16 11 P = .649 13 14 P = .297 17 10 P = .340
>5 c m 4 1 3 21 9 2 51 6 2 12 0
TNM stage
I 6 51 51 42
II 30 23 7 P = .001 16 14 P = .003 15 15 P = .008
III 25 9 16 6 19 5 20
I V 7 1 60 70 7
Lymph node
metastasis
Negative 36 28 8 P<. 001 21 16 P = .001 19 17 P = .001
Positive 32 10 22 6 26 5 27
Distant metastasis
Negative 61 37 24 P = .019 27 34 P = .037 24 37 P = .046
P o s i t i v e 7 1 60 70 7
aDenotes signiﬁcant diﬀerence among the three tissue types.
bDenotes signiﬁcant diﬀerence between colon cancer and normal colonic tissue.
cDenotes signiﬁcant diﬀerence between colon cancer and HPP.
factor 1, SDF-1) play an important role in the directional
regulation of hematopoiesis, migration of hematopoietic
cells, angiogenesis, and migration of metastatic tumor cells
[9]. CXCR4 is the most common chemokine expressed in
h u m a nt u m o r ss u c ha sb r e a s tc a n c e r ,c o l o r e c t a lc a n c e r ,a n d
ovarian cancer, and SDF-1 is highly expressed at sites of
metastasis including the lung, bone marrow, lymph nodes,
and liver [10]. Studies have shown that HIF-1α is a potent
inducer of both CXCR4 and SDF-1 expression in a variety of
cell types [11, 12].
Angiogenesis is known to play an important role in
the development of tumor growth and metastasis. Vascular
endothelial growth factor (VEGF) is the most important
andbestcharacterizedangiogenicfactor[13].VEGFpotently
increases vascular permeability and promotes the formation
of new blood vessels by stimulating endothelial cells to
migrate and divide [14]. HIF can directly activate the
expression of a number of proangiogenic factors. Of all those
induced by HIF, VEGF is particularly noteworthy since it
has potent angiogenic properties and is expressed in a largeClinical and Developmental Immunology 3
number of human tumors [15, 16]. The prognostic value
of overexpression of VEGF has been demonstrated in many
types of solid human cancers. Based on these studies, we
suggest that combinations of HIF-1α, CXCR4, and VEGF
expression in tumor tissue will be useful for predicting
clinicopathologic signiﬁcance and tumor metastasis.
In this study, we demonstrate high expression of HIF-
1α, CXCR4, and VEGF in human colon cancer specimens
using immunohistochemistry. Furthermore, we investigate
whether the expression of HIF-1α,C X C R 4 ,a n dV E G Fh a v ea
signiﬁcantcorrelationwithclinicopathologicfactorsofcolon
cancer.ThemRNAexpressionofHIF-1α,CX CR4,andVEGF
in colon cancer were quantiﬁed by real-time PCR.
2.MaterialsandMethods
2.1. Patients and Specimens. Colon cancer samples were col-
lected from 68 patients undergoing curative-intent surgery
at the Department of General Surgery of the First Peo-
ple’s Hospital of Changzhou (Jiangsu, China) from 2006
to 2008. Colon hyperplastic polyp tissue (HPP) samples
were obtained from 8 patients undergoing colonoscopy
with biopsy extraction at the Digestion Internal Medicine
Department during the years 2006–2008. There were also 10
normal colonic tissue samples adjacent to colon tumor (used
as controls). The histologic sections were reviewed by two
expert pathologists to verify the histologic diagnosis. None
of the patients had received any preoperative treatment. The
clinicopathologic characteristics of these patients are shown
in Table 1. Tumors were staged according to the American
Joint Committee on Cancer (AJCC) pathologic tumor-
node-metastasis(TNM)classiﬁcation.Informedconsentwas
obtainedfromallstudysubjectsbeforesamplecollectionand
these samples were used according to ethical standards.
2.2. Immunohistochemistry. Immunohistochemistry was
performed on the primary tumors as previously described
[17]. Sections were subjected to routine deparaﬃnization
and rehydration. Antigen retrieval was achieved by mi-
crowaving in 0.01mol/L citrate buﬀer for 10mins and
then cooling for 30min. Endogenous peroxidase activity
was inhibited by incubation with 3% hydrogen peroxide
in methanol for 20min and nonspeciﬁc binding was
blocked by incubation with 5% bovine serum albumin
in phosphate-buﬀered saline (PBS) at room temperature
(RT). After three PBS washes, the specimens were reacted
overnight at 4◦C with murine antihuman monoclonal
antibodies: anti-HIF-1α (diluted 1:200, Clone H1apha67,
ABCam), anti-CXCR4 (Clone 44716, R&D Systems, Inc.,
Minneapolis, MN, USA), or anti-VEGF (Clone JH121,
NeoMarkers, Lab Vision Corporation, Fremont, CA, USA).
After incubation with rat anti-mouse-IgG2b-horseradish
peroxidase, signal was developed with 3,3 –diaminobenzi-
dine tetrahydrochloride in Tris–HCl buﬀer (pH 7.6) con-
taining 0.02% hydrogen peroxide. The sections were then
counterstained with hematoxylin and mounted. Negative
controls were performed by replacing the speciﬁc primary
antibody with PBS.
2.3. Histological Assessment. Two clinical pathologists inde-
pendently evaluated the immunostaining results. When
an evaluation diﬀered, the ﬁnal decision was made by
consensus. Speciﬁc immunoreactivity was observed in the
cytoplasm and in nuclei of tumor cells. Cytoplasmatic
staining was observed homogeneously in the tumor cells;
nuclear immunoreactivity was heterogeneous in the tumor,
so the score was ascertained by consideration of both
staining density and intensity. The extent of the staining was
categorized into ﬁve semiquantitative classes based on the
percentages of positive tumor cells: 0 (<5% positive cells), 1
(6–25% positive cells), 2 (26–50% positive cells), 3 (51–75%
positive cells), and 4 (>75% positive cells). The intensity of
staining was also determined semiquantitatively on a scale
of 0–3 as follows: 0 (negative), 1 (weakly positive), 2 (mod-
erately positive), and 3 (strongly positive). Multiplication
of the intensity and the percentage scores gave rise to the
ﬁnal staining score: 0 (negative), + (1–4), ++ (5–8), and
+++ (9–12). For statistical analysis, tumors having a ﬁnal
staining score of negative or +, which showed a weak or
moderate/strong immunoreactivity were combined into a
low expression group and were compared to tumors with
scores of ++ or +++ as the high expression group.
2.4. . Real-Time PCR. The mRNA expression of HIF-1α,
CXCR4, and VEGF were quantiﬁed by real-time PCR in
diﬀerent fresh samples, including normal colonic tissue
samples (n = 6, negative control group), colon cancer
with lymph node metastasis samples (n = 6, lymph
node metastasis group), and colon cancer with distant
metastasis samples (n = 6, distant metastasis group). Total
RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions, and reverse
transcribed. mRNA expression of HIF-1α,C X C R 4 ,V E G F ,
and β actin was determined by real-time PCR using SYBR
Green master mix (ABI, Foster City, CA). The primers
for HIF-1α were 5 -GCTTGCTCATCAGTTGCCAC-3 and
5 -CATAACAAAACCATCCAAGGC-3 .T h ep r i m e r sf o r
CXCR4 were 5 -GCATGACGGACAAGTACAGGCT-3  and
5 -AAAGTACCAGTTTGCCACGGC-3 .T h ep r i m e r sf o r
VEGF were 5 -CAACATCACCATGCAGATTATGC-3  and
5 -TCGGCTTGTCACATTTTTCTTGT-3 . The primers
for β actin were 5 -ATGGAGGGGAATACAGCCC-3 
and 5 -TTCTTTGCAGCTCCTTCGTT-3 .D a t aw e r ec o l -
lected and quantitatively analyzed on an ABI Prism 7900
sequence detection system (ABI). β-actin gene was used
as an endogenous control for sample normalization. Dif-
ferences in the relative level of three markers normal-
ized to β actin can be estimated by diﬀerences in the
ratio.
2.5. Statistical Analysis. Diﬀerences were evaluated using
Statistical Package for Social Science software (version 11.0,
SPSS Inc., Chicago, IL). The association of staining intensity
with clinicopathologic patterns was assessed with Chi-
squared test and two-sided Fisher’s exact test to determine
the signiﬁcance of the diﬀerence between the the covariates.
Diﬀerences in mRNA expression levels were evaluated with4 Clinical and Developmental Immunology
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Figure 1: Expression of HIF-1α, CXCR4, and VEGF in colon primary tumor samples. Sections were subjected to routine deparaﬃnization
and rehydration. Antigen retrieval was achieved by microwaving in citrate buﬀer for 10min. The endogenous peroxidase activity was
inhibited by incubation with 3% hydrogen peroxide. The specimens were reacted overnight with anti-HIF-1α antibodies, anti-CXCR4
antibodies, and anti-VEGF antibodies, then were incubated with rat anti-mouse-IgG2b-horseradish peroxidase. The sections were then
counterstained with hematoxylin and mounted (see Section 2). HIF-1α staining was observed in the cytoplasm and in the nucleus of the
tumor cells, CXCR4, and VEGF staining was observed in the cytoplasm of tumor cells. Positive staining was observed as a brown color.
Weakly positive immunohistochemical staining of three molecules in (a) (HIF-1α), (c) (CXCR4), (e) (VEGF), respectively (×100). Strongly
positive immunohistochemical staining of three molecules in (b) (HIF-1α), (d) (CXCR4), (f) (VEGF), respectively, (×100).Clinical and Developmental Immunology 5
Table 2: Correlation of combined high expression of HIF-1α, CXCR4, and VEGF with lymph node status and distant metastasis.
Lymph node metastasis P value Distant metastasis P-value
Negative Positive Negative Positive
HIF-1α/CXCR4
(1) Both HIF-1α/CXCR4 low expression 16 (89) 2 (11) P< . 001 18 (100) 0 (0) P = .029
(2) One of HIF-1α/CXCR4 high expression 13 (57) 10 (43) (2) versus (3) 22 (96) 1 (4) (2) versus (3)
(3) Both HIF-1α/CXCR4 high expression 7 (26) 20 (74) P = .028 21 (78) 6 (22) P = .069
HIF-1α/VEGF
(1) Both HIF-1α/VEGF low expression 16 (84) 3 (16 ) P<. 001 19 (100) 0 (0) P = .021
(2) One of HIF-1α/VEGF high expression 14 (61) 9 (39) (2) versus (3) 22 (96) 1 (4) (2) versus (3)
(3) Both HIF-1α/VEGF high expression 6 (23) 20 (77) P = .007 20 (77) 6 (23) P = .062
CXCR4/VEGF
(1)Both CXCR4/VEGF low expression 15 (94) 1 (6) P< . 001 16 (100) 0 (0) P = .012
(2) One of CXCR4/VEGF high expression 13 (65) 7 (35) (2)versus (3) 100) 0 (0) (2)versus (3)
(3) Both CXCR4/VEGF high expression 8 (25) 24 (75) P = .004 25 (78) 7 (22) P = .035
HIF-1α/CXCR4/VEGF
(1)Fewer than HIF-1α, CXCR4, and VEGF high expression 31 (69) 14 (31) P<. 001 44 (98) 1 (2) P<. 001
(2)All of HIF-1α, CXCR4, and VEGF high expression 5 (22) 18 (78) 17 (74) 6 (26)
Student’st-test.Statisticaltestsweretwosided.P values<. 05
were considered to be statistically signiﬁcant.
3. Results
3.1. Patient Characteristics. A total of 68 patients with colon
cancer were included in the current analyses (Table 1).
The group was comprised of 41 males and 27 females,
with a median age of 63 years (range, 39–81 years). Forty
one patients (60%) evidenced tumor sizes of ≥5cm. The
postoperative stages of patients were I, II, III, and IV in 6,
30,25,and7patients,respectively.Thirtytwopatients(47%)
hadlymphnodemetastasis.Sevenpatients(10%)haddistant
metastasis.
3.2. HIF-1α, CXCR4, and VEGF Immunostaining in Diﬀerent
Colon Lesions. HIF-1α, CXCR4, and VEGF immunostaining
was quantitatively assessed and grouped into high- or low-
grade categories. Immunohistochemical expression of HIF-
1α was observed in the cytoplasm and in the nucleus of the
tumor cells in colon cancer cases but with diﬀerent staining
intensities (Figures 1(a) and 1(b)). Normal colonic mucosa
and HPP showed neither speciﬁc cytoplasmic nor nuclear
HIF-1α expression (Figures 2(a) and 2(b)). However, 30
colon cancer cases (44%) showed high HIF-1α expression
(Figure 1 (b)). There was no signiﬁcant correlation in the
cytoplasmic or nuclear expression between nonmetastatic
tumors and carcinomas with lymph node and distant
metastases. Immunohistochemical expression of CXCR4 was
observed predominantly in the cytoplasm of tumor cells
(Figures 1(c) and 1(d)). All ten normal colonic mucosa
cases and 8 HPP cases showed very weak CXCR4 staining
or no staining (Figures 2(c) and 2(d)). 41 colon cancer
cases (60%) showed high CXCR4 expression (Figure 1 (d)).
VEGF immunoreactivity was observed in the cytoplasm
of neoplastic cells in all investigated colon cancer cases
(Figures 1(e) and 1(f)). In colon cancer cases, high VEGF
expression was observed in 44 (65%) cases by immunohis-
tochemistry (Figure 1(f)). In comparison, VEGF staining of
normal colonic mucosa cases and HPP cases was negative
(Figures 2(e) and 2(f)). The diﬀerences in expression of
the three molecules (HIF-1α,C X C R 4 ,a n dV E G F )b e t w e e n
benign hyperplastic polyps and colon cancer tissues were all
found to be statistically signiﬁcant (P< . 05; Table 1).
3.3. Clinicopathological Signiﬁcance of HIF-1α, CXCR4,
and VEGF Expression. The relationships between HIF-1α,
CXCR4, and VEGF protein expression levels and clini-
copathologic variables are provided in Table 1. The high
expression rates of HIF-1α, CXCR4, and VEGF were 44%,
60%, and 65%, respectively. HIF-1α, CXCR4, and VEGF ex-
pression levels were correlated positively with TNM stage
(P = .001, P = .003, P = .008, resp.). There were no
statistically signiﬁcant diﬀerences in these molecules (HIF-
1α,CXCR4,andVEGF)withregardtopatientage(P = .878,
P = .801, P = .195, resp.), sex (P = .587, P = .639,
P = .807, resp.), or tumor size (P = .649, P = .297,
P = . 0340, resp.).
3.4. Association of Single or Combined HIF-1α, CXCR4,
and VEGF High Expression with Lymph Node Metastasis.
Statistical analysis shows that the incidence of lymph node
metastasis tends to be higher in patients with colon cancer
with high rather than low expression of HIF-1α,C X C R 4 ,o r
VEGF (P<. 001, P = .001, P = .001, resp.; Table 1). We
further compared correlation of lymph node metastasis of
colon cancer with combined high expression of both HIF-1α
and CXCR4, of both HIF-1α and VEGF, or of both CXCR4
and VEGF. Our data show that the incidence of lymph
node metastasis is signiﬁcantly higher (74%) in patients with
tumors highly expressing both HIF-1α a n dC X C R 4t h a ni n
those patients (43%) with tumors highly expressing only one6 Clinical and Developmental Immunology
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Figure 2: Expression of HIF-1α, CXCR4, and VEGF in normal colonic tissue and hyperplastic polyps (HPP). HIF-1α,C X C R 4 ,a n dV E G F
staining was negative in normal colonic tissue and HPP. Negative immunohistochemical staining of normal colonic tissue in (a) (HIF-1α),
(c) (CXCR4), (e) (VEGF), respectively (×100). Negative immunohistochemical staining of HPP in (b) (HIF-1α), (d) (CXCR4), (f) (VEGF),
respectively, (×100).Clinical and Developmental Immunology 7
of the molecules, or in those patients (11%) with tumors
not expressing either of these two molecules. Similar results
wereobservedinpatientswithtumorshighlyexpressingboth
HIF-1α and VEGF, or both CXCR4 and VEGF. At the same
time, there were statistically signiﬁcant diﬀerences in high
expression of these single molecules, and high expression
of any two of the three molecules with regard to lymph
node metastasis in patients with colon cancer (P = .028
for HIF-1α/CXCR4, P = .007 for HIF-1α/VEGF, and P =
.004 for CXCR4/VEGF; Table 2). In addition, as shown in
Table 2 out of the 32 cases with lymph node metastasis, 18
cases showed high expression of all HIF-1α,C X C R 4 ,a n d
VEGF molecules. 14 cases did not show high expression in
all three markers. Statistical analysis showed that combined
high expression of all three molecules (HIF-1α,C X C R 4 ,a n d
VEGF)issigniﬁcantlyassociatedwithlymphnodemetastasis
in patients with colon cancer as compared with cases not
showing such expression (P<. 001; Table 2).
3.5. Association of Single or Combined HIF-1α,C X C R 4 ,a n d
VEGF High Expression with Distant Metastasis. As shown
in Table 1 the incidence of distant metastasis tends to be
higher in patients with colon cancer with high rather than
low expression of HIF-1α,C X C R 4 ,o rV E G F( P = .019,
P = .037, P = .046, resp.). Moreover, experimental data
show that there are statistically signiﬁcant diﬀerences in high
expression of single CXCR4 or VEGF molecules, and high
expression of both CXCR4 and VEGF molecules with regard
to distant metastasis in patients with colon cancer (P = .035
for CXCR4/VEGF; Table 2). However, this result does not
applyinthecaseofanyothercombinationoftwoofthethree
molecules (P = .069 for HIF-1α/CXCR4, and P = .062 for
HIF-1α/VEGF; Table 2). We found a correlation of distant
metastasis of colon cancer with combined high expression
of all three HIF-1α, CXCR4, and VEGF markers. Out of
the 7 cases with distant metastasis, 6 cases showed high
expression of all HIF-1α, CXCR4, and VEGF molecules; 1
case showed high expression in fewer than three markers.
Statistical analysis indicates that combined high expression
of all three molecules is signiﬁcantly associated with distant
metastasis in patients with colon cancer as compared with
cases of high expression in fewer than all three (P<. 001;
Table 2).
3.6. The mRNA Expression of HIF-1α, CXCR4, and VEGF in
Normal Colonic Tissues and Colon Cancer Tissues. In order
to quantify the message RNA of these marks in colon cancer,
expressionofHIF-1α,CXCR4,andVEGFatthemRNAlevels
was analyzed by real-time PCR in diﬀerent samples. Results
demonstrated that mean HIF-1α mRNA expression levels
were 1.05 ± 0.58-fold in negative control group, 1.19 ±
0.52-fold in lymph node metastasis group, and 1.09 ± 0.32-
fold in distant metastasis group. There was no statistically
signiﬁcant diﬀerence in HIF-1α mRNA expression between
tumorgroupsandcontrolgroup.Incontrast,CXCR4mRNA
expression levels were signiﬁcantly higher in lymph node
metastasis group (15.91 ± 12.14 fold) and distant metastasis
group (23.20 ± 14.84 fold) than in normal colonic tissue
(6.23 ± 4.66 fold). Statistical analysis has shown that there
wasasigniﬁcantdiﬀerencebetweenthemeanCXCR4mRNA
levels for all groups (lymph node metastasis group or distant
metastasis group vs negative control group, resp., P<. 05,
Figure 3). In addition, lymph node metastasis group and
distant metastasis group signiﬁcantly overexpressed VEGF
mRNA compared with negative control group, respectively,
(9.99 ± 3.38-fold in lymph node metastasis group or 10.27 ±
5.90-fold in distant metastasis group versus 4.68 ± 1.28-fold
in negative control group, resp., P<. 05, Figure 3).
4. Discussion
In this study, we investigated HIF-1α, CXCR4, and VEGF
expression in human colon primary tumor samples using
immunohistochemistry. Staining was observed in the cyto-
plasm or in the nucleus of tumor cells. The results demon-
strate that there is a statistically signiﬁcant correlation
between human colon cancer TNM stage and single HIF-
1α, CXCR4, and VEGF expression levels. We also found
that high expression of HIF-1α, CXCR4, and VEGF is
associated with increased metastatic potential in human
colon cancer. Furthermore, concomitant expression of the
three molecules may be considered in association with the
disease-free survival of all patients after curative resection.
We also investigated that expression of HIF-1α,C X C R 4 ,a n d
VEGF at the mRNA levels was analyzed by real-time PCR.
The experiment results demonstrated that CXCR4 mRNA
and VEGF mRNA expression levels were signiﬁcantly higher
in fresh colon cancer samples than in normal colonic tissue,
whereas tumoral HIF-1α expression at the mRNA levels was
not higher.
Tumor hypoxia is a microenvironmental factor that
has been shown to aﬀect the malignant progression of
transformed cells [18]. In the presence of oxygen, HIF-1α
is hydroxylated by a family of prolyl hydroxylases and sub-
jected to rapid ubiquitination and proteasomal degradation
mediated by the Von-Hippel Lindau-dependent pathway
(VHL) [19, 20]. Under hypoxic conditions, hydroxylation is
inhibited, resulting in the stabilization of HIF-1α protein,
which translocates into the nucleus, dimerizes with HIF-
1α, and activates HRE, many of which are important for
proliferation, apoptosis, angiogenesis, and migration [21].
Previous studies have indicated that activation of HIF-1α has
been identiﬁed in many solid tumors including carcinomas
of the gastrointestinal tract. Our results indicated that high
expressionofHIF-1αpr oteinismuchmor efr equentinc olon
cancer tissues than in normal tissues or nontumor lesions,
while the expression of HIF-1α signiﬁcantly correlates with
tumor TNM stage (P = .001), lymph node status (P<. 001),
and distant metastases (P = .019). In accordance with our
results, Simiantonaki et al. [22] found that higher HIF-
1α expression is associated with lymph node metastasis or
distant metastases.
HIF-1α activation correlates with metastasis and can
promote metastasis through the regulation of key factors8 Clinical and Developmental Immunology
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Figure 3: Expression of HIF-1α, CXCR4, and VEGF mRNA in normal colon tissues and colon cancer. The mRNA expression of HIF-1α,
CXCR4, and VEGF were quantiﬁed by real-time PCR in diﬀerent samples, including normal colonic tissue samples (n = 6, negative control
group), colon cancer with lymph node metastasis samples (n = 6, lymph node metastasis group), and colon cancer with distant metastasis
samples (n = 6, distant metastasis group). Total RNA was isolated using TRIzol according to the manufacturer’s instructions and reverse
transcribed. mRNA expression of HIF-1α,C X C R 4 ,V E G Fa n dβ actin was determined by real-time PCR using SYBR Green master mix
(see Section 2). Diﬀerences in the relative level of three markers normalized to β actin can be estimated by diﬀerences in the ratio. CXCR4,
15.91 ± 12.14-fold in lymph node metastasis group or 23.20 ± 14.84-fold in distant metastasis group versus 6.23 ± 4.66-fold in negative
control group, respectively, P<. 05, VEGF, 9.99 ± 3.38-fold in lymph node metastasis group or 10.27 ± 5.90-fold in distant metastasis group
versus 4.68 ± 1.28-fold in negative control, respectively, P<. 05.
governing tumor cell metastatic potential, including E-
cadherin, lysyl oxidase (LOX), connective tissue growth fac-
tor (CTGF), and plasminogen activator inhibitor-1 (PAI-1),
CXCR4 [23–27]. The chemokine receptor CXCR4 selectively
binds the CXC chemokine, SDF-1. Binding of SDF-1 to
CXCR4 induces migration of cancer cells into normal tissue,
where the cells proliferate and form metastatic tumors [28].
Schimanski et al. [29] reported in accordance with our
results, that high expression of CXCR4 in colorectal cancer
is signiﬁcantly associated with advanced UICC tumor stages
and with lymphatic or hematogenic metastasis. Recently,
new evidence indicated that hypoxia may aﬀect the tumor
migration process by altering the expression of CXCR4 via
activation of HIF-1α. Zagzag et al. [30] reported that CXCR4
expression in glioma cells can be controlled by hypoxia and
the levels of HIF-1α, and is associated with increased glioma
cellmigration.Wang etal.[31]alsodemonstratedthatexpo-
sure to hypoxia signiﬁcantly enhances CXCR4 expression
levels in N9 microglia cells. Blockade of HIF-1α activation
by inhibitors of the phosphoinositide-3-kinase (PI3K)/Akt
signaling pathway abrogates both hypoxia-induced CXCR4
upregulation and cell-migration acceleration. Their results
point to a crucial role for the Hypoxia-HIF-1α-CXCR4
pathway during microglia migration. Therefore, we analyzed
the correlation between the high expression of both HIF-
1α and CXCR4 and clinicopathologic signiﬁcance in human
colon cancer samples. Our results show that high expression
of both molecules is more predictive of lymph node involve-
ment as compared with that of a single molecule alone.
However, combined high expression of both molecules is not
signiﬁcantly associated with distant metastasis as compared
with that of a single molecule alone (P = .062).
VEGF is the most well-studied angiogenic factor. The
most potent inducer of VEGF gene expression is hypoxia
[32]. VEGF is transcriptionally regulated by HIF-1α,w h i c h
translocates to the nucleus following hypoxia-induced stabi-
lization, dimerizes with HIF-1β (ARNT), and activates HRE
in the promoter region of the VEGF gene [33]. VEGF is
also regulated by HIF-independent mechanisms including
other transcription factors and coactivators [34], micro-
RNAs [35], and inﬂammatory mediators [36]. Mizukami
et al. [37] reported that VEGF may be induced by hypoxia
through HIF-dependent and HIF-independent pathways,
and K-ras also can induce VEGF in hypoxia independent
of HIF-1 in colon cancer. These data suggest the existence
of multiple mechanisms regulating the hypoxic induction of
VEGF. In our study, we ﬁrst demonstrated VEGF expression
in human colon primary tumor tissue using immunohisto-
chemistry. High expression of VEGF signiﬁcantly correlates
with tumor TNM stage (P = .008), lymph node status
(P = .001), and distant metastasis (P = .046). Furthermore,
we analyzed the concomitant expression of HIF-1α and
VEGF in colon cancer samples, demonstrating that 63%
of colon cancer with lymph node involvement showed
high expression of both HIF-1α and VEGF, and that 6
out of 7 of the cases with both HIF-1α and VEGF high
coexpression showed distant metastasis. Statistical analysis
indicated that combined high expression of both HIF-
1α and VEGF is signiﬁcantly associated with lymph node
metastasis as compared with that of a single molecule’s high
expression alone (P = .007) and cases without distantClinical and Developmental Immunology 9
metastasis (P = .067). Therefore, we provide clinical
evidence that coexpression of HIF-1α and VEGF may play
an important role in colon cancer growth and lymph node
metastasis.
Recently, some studies have shown that angiogenesis
mediated by CXCR4 is regulated at the receptor level by
VEGF. CXCL12 can induce secretion of VEGF in human
arterial endothelial cells [38]. The interaction of CXCR4 and
CXCL12 may promote tumor progression and metastasis
via the induction of VEGF-mediated angiogenesis [39].
Therefore, we analyzed the correlation between coexpression
of both molecules (CXCR4 and VEGF) and metastasis. We
found a positive correlation between coexpression of both
molecules and lymph node metastasis (P = .004) and distant
metastases (P = .035), as compared with that of a single
molecules high expression alone.
Furthermore, we analyzed the clinicopathologic signiﬁ-
canceof combined HIF-1α, CXCR4, and VEGF expression in
colon cancer. We found that 18 out of 23 (78%) of the cases
with all three molecules coexpressed showed lymph node
metastasis and 6 out of 23 (26%) of the cases with all three
molecules coexpressed showed distant metastasis. Statistical
analysis indicates that HIF-1α, CXCR4, and VEGF high
expression signiﬁcantly correlates with lymph node status
(P<. 001) and distant metastasis (P<. 001) as compared
with cases of fewer than all three molecules showing high
expression.
Lastly, in order to quantify the message RNA of HIF-
1α, CXCR4, and VEGF in colon cancer, the three marks
expression at the mRNA levels were analyzed by real-
time PCR. Results demonstrated that CXCR4, and VEGF
expression at the mRNA levels by real-time PCR were
similar at the protein levels by immunohistochemistry in
colon cancer. However, there was no statistically signiﬁcant
diﬀerenceinHIF-1αmRNAexpressionbetweencoloncancer
group and normal colonic group. Under both normoxia
and hypoxia, HIF-1α mRNA is expressed constitutively in
many cell types, including cancer cells and endothelial cells
[40]. Several putative sites for factors that activate and
repress transcription were identiﬁed in the HIF1A gene
promoter; some transcription factors, like Sp1, were shown
to contribute to the constitutive transcription of the HIF-1α
mRNA [41].
In summary, we have demonstrated that HIF-1α,
CXCR4, and VEGF are highly expressed in colon can-
cer samples as demonstrated using immunohistochemistry.
Combinedhighexpressionofanytwoofthemissigniﬁcantly
associated with lymph node metastasis. However, no two
of them in combination show a relationship with distant
metastasis, except in the case of CXCR4/VEGF. Moreover,
our data also indicate that the combined high expression
of HIF-1α, CXCR4, and VEGF is signiﬁcantly associated
with lymph node metastasis and distant metastasis. These
experimental results provide a possible basis for disease-
free survival of all patients after curative resection to predict
tumor recurrence and metastasis.
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